Morphic Therapeutic, Inc.

Preceres Inc.

Eisai R&d Management Co., Ltd.

Cheng Zhong

Aleksey I Gerasyuto

Blaise S Lippa

Fu-Yang Lin

Dawn M Troast

Bruce Nelsen Rogers

Matthew Gregory Bursavich

Bryce Alden Harrison

Kristopher N Hahn

Byungchan Kim

Tyler Day

Kyle D Konze

Brian Sosa

Mats A Svensson

James E Dowling

Eugene R Hickey

Alexey Alexandrovich Lugovskoy

Richard Wayne Heidebrecht, Jr

Qi Qiao

Andrea Bortolato

Robert Zahler

Salma Rafi

Evelyne Houang

Dan Cui

Dominic J Reynolds

Andrew Cook

Sudeep Prajapati

Jason T Lowe

James Palacino

Xiang Liu

Shelby Ellery

Thiwanka Samarakoon

Megan Sheehan

Ryan Brawn

Angrea Bortolato

Disclosed are small molecule inhibitors of αvβ6 integrin, and methods of using them to treat a number of diseases and conditions.

Inhibiting (α-v)(β-6) integrin

Disclosed are small molecule antagonists of α4β7 integrin, and methods of using them to treat a number of specific diseases or conditions.

Antagonists of human integrin α4β7

Disclosed are small molecule inhibitors of &#x3b1;v&#x3b2;6 integrin, and methods of using them to treat a number of diseases and conditions.

Inhibiting (&#x3b1;-v)(&#x3b2;-6) integrin

The present disclosure provides pladienolide compounds, pharmaceutical compositions containing such compounds, and pladienolide compounds for use in methods of medical treatment. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are pladienolide compounds for use in methods of treating cancers by administering at least one pladienolide compound disclosed herein and at least one additional therapy

Certain aryl pladienolide compounds and methods of use

Disclosed are small molecule antagonists of human &#x3b1;&#x3b2;integrin, and methods of using them to treat a number of diseases and conditions.

Inhibiting human integrin (alpha-4) (beta-7)

Disclosed are small molecule antagonists of &#x3b1;4&#x3b2;7 integrin, and methods of using them to treat a number of specific diseases or conditions.

Antagonists of human integrin (&#x3b1;4)(&#x3b2;7)

Inhibiting human integrin (&#x3b1;-4) (&#x3b2;-7)

Inhibiting (&#x3b1;-V)(&#x3b2;-6) integrin

Antagonists of human integrin &#x3b1;4&#x3b2;7

The present disclosure is directed to hydrazinyl lipidoids, formulations thereof further comprising at least one active agent, as well as methods of delivering the at least one active agent to a target organism.

Hydrazinyl lipidoids and uses thereof

Growing community of inventors

Belmont, MA, United States of America

Cheng Zhong